Skip to main content
Signal8

Full Access with Signal8 Pro, $49/mo billed annually.

Gevo, Inc. (GEVO) Form 10-Q — Aug 6, 2026

$GEVOForm 10-QFiled Aug 6, 2026, 5:08 PM ET0001628280-26-054462Original filing

Gevo's Q2 2026 10-Q shows revenue of $46.5 million, up 7% year over year, but a net loss attributed to Gevo of $176.9 million, or $(0.75) per share, versus net income of $2.1 million a year ago. The swing was driven by a $135.8 million impairment of long-lived assets and a $39.8 million allowance for credit losses on refundable deposits. The charges stem from a strategic retreat: Gevo discontinued its ATJ-60 sustainable aviation fuel project, abandoned the larger ATJ-180 configuration, and in April 2026 withdrew its application for a roughly $1.6 billion DOE loan guarantee. Resources are being redirected to the smaller ATJ-30 SAF platform planned for the Gevo North Dakota site.

Key figures

Revenue
46501000
Total Debt
175000000
Total Assets
490714000
Cash Position
58147000
Shares Outstanding
247237104
H1 2026 revenue
89449000
Term loan principal
175000000
Term loan interest rate
12.00%
Cfpc credits generated h1
32000000
Revolving credit facility
20000000
Gevond q2 operating income
18966000
Stock repurchase remaining
20300000
Doe loan guarantee withdrawn
1600000000
H1 ethanol production gallons
34092830
H1 ethanol production yoy pct
22
Atm program remaining capacity
500000000
Impairment of long lived assets
135788000
Loss on extinguishment of bonds
10304000
H1 carbon sequestered metric tons
90334
Bond redemption prepayment penalty
6506000
Red trail acquisition consideration
210000000
Allowance for credit losses on refundable deposits
39782000

Price after filing

1 day: -1.3%7 days: +4.5%30 days: +5.8%

Close on the filing date to close N calendar days later (from $1.55). Historical, not a forecast.

AI analysis

Red flags7 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.